The Living Digital Twin: Predictiv's Whole-Genome Platform for Lifelong Personalized Health

In the traditional model of healthcare, patients receive treatment based on population averages rather than individual biology. A medication that works for one person causes debilitating side effects for another. A disease that could have been prevented with early intervention goes undetected until symptoms appear. For individuals and families navigating this "one size fits all" system, the consequences can be measured in missed diagnoses, adverse drug reactions, and preventable suffering.

Predictiv was founded to transform this paradigm. The company emerged from a deeply personal story: co-founder Sijung Yun, a research professor at Johns Hopkins University with training in physics and postdoctoral work at the National Institutes of Health, watched his father struggle with a rare stomach cancer. In searching for answers, Yun and his colleagues analyzed his father's DNA and discovered the genetic variant that may have caused the cancer. The realization that earlier knowledge could have predicted and possibly prevented the disease sparked a mission to make precision health accessible, affordable, and understandable for everyone. Today, Predictiv offers a living digital twin platform that integrates whole-genome sequencing, health history, lifestyle factors, and ongoing scientific research into a dynamic model that evolves throughout a person's lifetime.

The company's revenue model is built on direct-to-consumer sales of its DNA testing and digital twin platform, with a one-time test generating lifetime insights. Predictiv generates income through kit sales, with customers paying for whole-genome sequencing and ongoing access to the interactive digital twin platform. Additional revenue streams include the PharmSmart mobile app, which provides drug interaction checking and prescription price comparison, creating a lower-cost entry point that can convert users to the full platform. The company's CLIA-certified laboratory ensures clinical-grade analysis, while board-certified doctors, licensed genetic counselors, and registered nurses provide professional oversight and consultation.

The Whole-Genome Foundation for Comprehensive Insight

Predictiv's most distinctive competitive advantage is its use of whole-genome sequencing, analyzing over 20,000 genes rather than the limited panels offered by consumer genetic testing companies. This comprehensive approach captures the full spectrum of genetic variants that influence disease risk, medication response, and health optimization. Unlike tests that must be repeated as science advances, Predictiv's platform reanalyzes the complete genome as new research emerges, ensuring that insights remain current throughout the customer's lifetime. For individuals concerned about hereditary cancer risk, cardiovascular conditions, or medication sensitivities, this depth of analysis provides answers that narrow panels cannot.

The Digital Twin Architecture for Dynamic Health Modeling

Predictiv has built a platform that integrates genetic data with health history, lifestyle factors, and medication records to create a living digital model of each individual's health. The digital twin evolves as users update their health information and as new scientific research becomes available, providing a continuously improving picture of disease risk, medication compatibility, and wellness optimization. For users managing chronic conditions or navigating complex treatment decisions, this dynamic model provides decision support that static reports cannot offer. For the company, the ongoing engagement creates opportunities for continued customer relationships beyond the initial test.

The Pharmacogenomics Capability for Medication Safety

Predictiv's PharmSmart platform addresses one of the most immediately actionable applications of genetic information: predicting how individuals will respond to medications. Research shows that approximately 97 percent of individuals carry at least one gene variant that may affect medication response, and studies have demonstrated that patients using DNA-guided prescribing experience 30 percent fewer serious side effects. PharmSmart provides up-to-date dosing guidelines for over 75 medications across mental health, cardiovascular, pain management, and infectious disease categories, enabling physicians to select the right drug at the right dose before treatment begins. For individuals who have experienced adverse reactions or ineffective treatments, this capability can be transformative.

The Data Ownership Model for Patient Control

Predictiv operates on a principle that individuals should own their health data, with control over how it is used, shared, and accessed. Unlike many health technology companies that claim ownership or reserve rights to sell de-identified data, Predictiv's terms ensure that customers retain ownership and consent is required for any data sharing. This commitment to privacy and autonomy builds trust in a market where data security concerns have limited adoption of genetic testing.

For individuals seeking to move beyond reactive sick care to proactive well care, Predictiv offers the whole-genome digital twin that integrates nature and nurture into a lifelong health resource. Dr. Sijung Yun and his team have built an organization where advanced genomics, artificial intelligence, and human-centered care combine to deliver personalized health insights that evolve with each individual. With a platform that screens over 20,000 genes, updates continuously with new research, and provides 24/7 access to care professionals, Predictiv stands as the essential partner for those ready to take control of their health story.

Sijung Yun, PhD, PRESIDENT & CEO, CO-FOUNDER

"We believe health systems need to shift from 'sick' care to 'well' care. Everyone should have access to affordable personalized and precision health care. Diseases and poor health outcomes can be predicted and prevented with the right tools and people."